Yan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract
|
|
- Jeffrey Sherman
- 5 years ago
- Views:
Transcription
1 Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3 1 Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing , China; 2 Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing , China; 3 Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing , China *These authors contributed equally to this work. Correspondence to: Yan Wang. Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing , China. wangyanyifu@126.com; Jianming Ying. Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing , China. jmying@hotmail.com. Abstract Objective: To investigate the clinical features of patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, and the treatment outcomes of EGFR tyrosine kinase inhibitors (TKIs) in these patients. Methods: We retrospectively analyzed the data of 128 NSCLC patients pathologically diagnosed with uncommon EGFR mutation in the Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Hospital from January 2010 to December 2015, including 40 advanced patients who received EGFR-TKI. Results: Among the total 128 patients, 11 patients were non-adenocarcinoma, including squamous carcinoma (3.9%), adenosquamous carcinoma (2.3%), large cell carcinoma (0.8%), and composite neuroendocrine carcinoma (1.6%). Single mutations accounted for 75.0% (96/128), including G719X (29.7%), S768I (18.0%), 20 exon insertion (13.3%), L861Q (12.5%), De novo T790M (0.8%), and T725 (0.8%). Thirty-two patients harbored complex mutations. Forty advanced patients received EGFR-TKI, the objective response rate (ORR) was 20.0%, the disease control rate (DCR) was 85.0%, and the progression-free survival (PFS) was 6.4 [95% confidence interval (95% CI), ] months. The exploratory analysis of tumor response and PFS in 33 patients with G719X/S768I/L861Q subtypes showed that ORR was 21.2% (7/33), the DCR was 93.9% (31/33), and PFS was 7.6 (95% CI, ) months. Patients with exon 20 insertion mutation and De novo T790M experienced rapid disease progression with PFS no more than 2.7 months. Conclusions: Uncommon EGFR-mutant NSCLCs are heterogeneous, EGFR-TKIs can have different efficacy in this specific subtype, and thus further individual assessment is required for each case. Keywords: Non-small cell lung cancer; EGFR; uncommon mutation; target therapy Submitted Sep 13, Accepted for publication Feb 10, doi: /j.issn View this article at:
2 Chinese Journal of Cancer Research, Vol 29, No 1 February Introduction Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death (1,2). The traditional therapy was based on cancer histology. However, since the identification of epidermal growth factor receptor (EGFR) in 2004, therapy paradigm has been changed toward molecularly driven strategy based on driver mutations in genes and specific inhibitors of these pathways. EGFR is the product of oncogene C-erbB-1 (HER-1). It is not created equally in different races, with higher mutation incidence in Asian than in Caucasian (30% 60% vs. 10% 20%) (3-5). EGFR mutation is an effective factor of EGFR tyrosine kinase inhibitors (TKIs) treatment response in NSCLC, of which short in-frame deletion in exon 19 (19 del) and L858R substitution account for 90%. These common EGFR mutations are associated with good efficacy of EGFR-TKI, and the objective response rate (ORR) and progression-free survival (PFS) are approximately 70% and months, respectively (3-6). The remaining 10% of EGFR mutations are generally called uncommon mutation, including a heterogeneous group of molecular alterations within exon The clinical characteristics and therapeutic effects of EGFR- TKIs on NSCLC with uncommon EGFR mutation subtypes remain unclear. Here we summarized the clinical data of patients who harbored uncommon EGFR mutations in order to perform a retrospective analysis of NSCLC patients with uncommon EGFR mutations and to reveal their association with treatment outcomes after TKI therapy. Materials and methods Patients From January 2010 to December 2015, patients with histologically diagnosed uncommon EGFR mutation by amplification refractory mutation system (ARMS) or direct sequencing in the Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Hospital were enrolled. Uncommon EGFR mutations were defined as all mutations except 19 del, L858R point mutation or acquired T790M mutation. Pathological diagnosis was based on specimens from surgery, percutaneous transthoracic biopsy, transbronchial biopsy, lymph node biopsy, or metastatic tumor biopsy. Patients were eligible for TKI efficacy analysis if they had stage IIIB/IV (American Joint Committee on Cancer AJCC TNM Staging system, 7th edition) NSCLC with uncommon EGFR mutation and had been treated with EGFR-TKIs (gefitinib, erlotinib or icotinib) for more than one month. The type of EGFR TKIs depended on the physicians discretion. Patients were given 250 mg of gefitinib daily or 150 mg of erlotinib daily, whereas patients who were treated with nicotine received 125 mg three times daily. Patients received TKI as adjuvant therapy or with other concomitant anticancer therapy were excluded. Follow-up and effectiveness evaluation of TKI All enrolled patients were under regular clinical follow-up exams including a physical examination, chest enhanced computed tomography (CT) (including liver and adrenal glands) and routine laboratory test one month after initial treatment and then every 2 months thereafter to evaluate the response to treatment. Baseline assessments were carried out before treatment. The responses were defined as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) according to the criteria of the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). The treatment response and PFS were determined by review of CT by one chief physician and one attending doctor, and sometimes another one chief physician was needed when different evaluation results occurred. Disease control status comprised CR, PR and SD. The cutoff date was December 31, PFS was measured from the first day of EGFR- TKI treatment until the clinical sign of disease progression or death or cutoff date. Ethics This retrospective study was approved by the Institutional Ethics Review Board of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. Informed consent was exempted by the board due to the retrospective nature of this research. Patient records were anonymized and deidentified prior to analysis. Statistical analysis All analyses were carried out by SPSS software (Version 13.0; SPSS Inc., Chicago, IL, USA). Demographic and clinical data were summarized as medians with ranges for continuous variables, and categorical variables were
3 20 Zhang et al. NSCLC with uncommon EGFR expressed as the means of absolute and percentage numbers. PFS after EGFR-TKI treatment was estimated by the Kaplan-Meier method to assess the time to death or progression. Results Characteristics of NSCLC patients with uncommon EGFR From January 2010 to December 2015, excluding 19 del, L858R point mutation or acquired T790M mutation, 128 patients with driver oncogene detection were enrolled. Among these patients, 59.4% were women, 62.5% were never smokers, and the median age was 58 years old. Eleven patients were non-adenocarcinoma, including squamous carcinoma (3.9%), adenosquamous carcinoma (2.3%), large cell carcinoma (0.8%), and composite neuroendocrine carcinoma (1.6%) (Table 1). Table 1 Clinicopathological features of patients with NSCLC (N=128) Characteristics Case No. % Age (year) Median (range) Gender 58 (31 83) Female Male Smoking Never Ever Histology Adenocarcinoma Squamous carcinoma Adenosquamous carcinoma Composite neuroendocrine carcinoma Large cell carcinoma TNM staging I II III IV EGFR mutation testing ARMS Direct sequencing NSCLC, non-small cell lung cancer; TNM, tumor-node-metastasis; EGFR, epidermal growth factor receptor; ARMS, amplification refractory mutation system. Types of EGFR uncommon mutation Of all 128 patients, single mutations account for 75.0% (96/128), including G719X (29.7%), S768I (18.0%), 20 exon insertion (13.3%), L861Q (12.5%), De novo T790M (0.8%), and T725 (0.8%). Complex mutations were detected in 32 patients: L858R + 19 del in 2 patients, L858R/19 del + uncommon mutation in 15 patients, and uncommon + uncommon mutation in 15 patients (Table 2). Table 2 Types of EGFR uncommon mutation (N=128) Uncommon EGFR mutation Case No. % Single mutation G719X S768I Exon 20 insertion L861Q T790M (primary mutation) T725T synonymous mutation Complex mutation Sensitive+sensitive mutation L858R + 19 del Sensitive + uncommon mutation L858R + De novo T790M L858R + S768I L858R + L861Q del + G719X del + De novo T790M del + L861Q Uncommon + uncommon mutation G719X + S768I G719X + De novo T790M G719X + E709A G719X + L861Q EGFR, epidermal growth factor receptor; 19 del, exon 19 deletion. EGFR TKI effectiveness and survival in patients with uncommon EGFR mutation Forty advanced patients receiving EGFR TKI treatment were eligible for TKI effectiveness analysis. Gefitinib was administered in 26 patients, and erlotinib and icotinib were administered in 7 patients respectively. EGFR TKIs were used as first-line treatment for 21 patients, second line for 15, and third or later lines for 4 patients. By the time of cutoff date, 8 patients still had cancer remained controlled.
4 Chinese Journal of Cancer Research, Vol 29, No 1 February The ORR in those 40 patients was 20.0%, the disease control rate (DCR) was 85.0% and the PFS was 6.4 [95% confidence interval (95% CI), ] months (Figure 1). Figure 1 The PFS analysis of patients with EGFR uncommon mutations treated with EGFR-TKIs. PFS, progression-free survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. In the subset analysis, 2 patients with L858R + 19 del achieved PR, and PFS was 6.0 months and 6.2 months, respectively. Two patients with 20 exon insertion mutation experienced rapid disease progression after one-month treatment. De novo T790M occurred concurrently with sensitive mutations, L858R (2/3) or exon 19 deletion (1/2). Two patients with De novo T790M + L858R mutation had rather limited benefit from EGFR-TKI, with one having progressed disease after one month of TKI therapy and the other one suffering SD with PFS only 2.7 months. However, the PFS of the patient with De novo T790M + 19 del reached as long as 8.1 months. The exploratory analysis of tumor response and PFS in 33 patients with G719X/S768I/L861Q subtypes showed the DCR was 93.9% (31/33), ORR was 21.2% (7/33), and PFS was 7.6 (95% CI, ) months. The subset analysis of G719X/S768I/L861Q subtype is demonstrated in Table 3. Remarkably, a 64-year-old Chinese male, with 20 packyears smoking history, was detected with S768I mutation. Nicotine was given 125 mg three times a day as second-line therapy. The tumor still maintained SD at the time of cutoff date, totally 31 months of TKI treatment. Discussion As the efficacy of EGFR TKIs for the treatment of patients Table 3 Tumor response and PFS in G719X/S768I/L861Q subtypes EGFR mutation DCR n (%) ORR PFS [median (range)] (month) G719X (N=22) 20 (90.9) 5 (22.7) 7.6 ( ) G719X (n=14) G719X + S768I (n=5) G719X + L858R (n=2) G719X + E709A (n=1) S768I (N=11) 10 (90.9) 3 (27.3) 8.0 ( ) S768I (n=4) S768I + G719X (n=5) S768I + L858R (n=2) L861Q (N=5) 5 (100) 0 (0) 5.7 ( ) L861Q (n=4) L861Q + L858R (n=1) EGFR, epidermal growth factor receptor; DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival. with uncommon mutations has not yet been fully elucidated, more research and data should be encouraged to share for clinical practice. In this study, we reported the clinical data of 128 NSCLC patients with uncommon EGFR mutations diagnosed in the Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and Beijing Hospital. We observed that uncommon EGFR mutations were harbored not only in adenocarcinoma, but also in squamous carcinoma, adenosquamous carcinoma, large cell carcinoma and carcinoid. Forty patients received EGFR-TKIs, the ORR was 20.0% and the PFS was 6.4 (95% CI, ) months. Both results were inferior to the patients with common EGFR mutations in previous reports (5,6). Mutations on G719X/S768I/L861Q constituted a major part of uncommon EGFR mutations, accounting for nearly 6% of EGFR mutations (7). One hundred and sixty-one patients with stage IIIB/IV lung adenocarcinoma bearing G719X/S768I/L861Q mutations were enrolled in a study from Taiwan, China. After receiving EGFR-TKI treatment, patients with those uncommon mutations exhibited a significantly inferior tumor response rate (41.6% vs. 66.5%; P<0.001) and PFS (median, 7.7 vs months; P<0.001) than patients with common mutations in the controlled group (8). The exploratory analysis of G719X/S768I/L861Q subtypes in our study showed that
5 22 Zhang et al. NSCLC with uncommon EGFR the PFS was 7.6 (95%CI, ) months, which was consistent with the previous research. G719X in exon 18 was found with the highest incidence in our cohort. The frequency of exon 18 mutations was about 5%, among which G719X accounted for the majority. An in vitro study had indicated that the affinity of G719X mutation with ATP was lower than that of L858R but higher than that of wild type (9). A six-fold higher concentration of gefitinib was required to inhibit the growth of cells expressing G719X compared with cells expressing L858R (10). A previous study reported patients with G719X single mutation or compound mutations had a median PFS of 8.1 months and a median OS of 16.4 months (11). After receiving EGFR-TKI treatment in our study, patients with G719X single mutation or compound ones exhibited an ORR of 22.7% and a median PFS of 7.6 months. Therefore, first-generation EGFR-TKIs were active in G719X mutations though less effective than in common mutations. However, a preclinical and clinical study demonstrated that second-generation EGFR-TKI afatinib may be an optimal choice for G719X mutations, with a median PFS of 13.8 months (12). Additionally, E709X, S720P, V689M and insertion mutations in 18 exon were also rarely reported in previous studies. In our study, one of two patients with G719X + E709A received EGFR- TKI and experienced a PFS of 6.3 months. It was less effective than single G719X mutation due to E709A reducing the sensitivity of G719X to EGFR-TKI as demonstrated in an in vitro study (13,14). In our current study, another uncommon mutation with high incidence was S768I. The frequency of mutation in exon 20 differed in diverse population, ranging from 1% to 17% (15-17). The efficacy of EGFR-TKI in S768I mutation was controversial. Kancha et al. showed in preclinical study that the IC 50 value of gefitinib or erlotinib in S768I was higher than that of G719X and L861Q. In other words, S768I may be resistant to EGFR-TKI (10). However, a clinical study demonstrated similar response in S768I compared with 719X and L861Q (8). In our population, S768I mutation had favorable response (ORR, 27.3%; DCR, 90.9%) and survival (PFS, 8 months). Additionally, one patient harbored S768I with icotinib treatment as second-line therapy experienced 31 months of TKI treatment at the time of cutoff date and still maintained SD. Similarly, Masago et al. also reported the case of a patient harboring S768I with gefitinib as secondline therapy had a PFS as long as 15 months. Although National Comprehensive Cancer Network (NCCN) Guidelines have not recommended it as drug-sensitive mutation, S768I indeed seemed to be sensitive to EGFR- TKIs (18,19). The mutation of L861Q accounted for approximately 2% of EGFR mutations (20). The response of L861Q to EGFR-TKI in previous reports was inconsistent. A number of studies demonstrated that first-generation EGFR-TKI was active in patients with L861Q mutations though less effective than in those with common mutations, with a PFS of 8.9 months and an OS up to months (7,10,21). Therefore, L861Q was recommended as TKI-sensitive mutation in NCCN Guidelines. However, there was a study elucidated first-generation EGFR-TKIs might be an ineffective treatment option for this patient population (22). In current study, the PFS of patients with L86IQ was 5.7 (95%CI, ) months. Thus, cancers with L861Q mutation were probably heterogeneous and associated with different EGFR TKIs treatment responses. EGFR exon 20 insertion mutation (approximate 10% of all EGFR mutations) was generally associated with insensitivity to available TKIs (23). Consistent with the previous study, patients with exon 20 insertion in our cohort suffered progressed disease one month after TKI therapy. However, it was reported that the effectiveness of EGFR-TKI in exon 20 insertion mutation depended on the type and location of the insertion, for instance, the specific EGFR-A763 Y764ins alteration was associated with a high DCR (13). Therefore, EGFR-TKI was not recommended as the first-line therapy for EGFR exon 20 insertion mutation in clinical practice. EGFR T790M was considered as the most common mechanism of resistance to first-generation EGFR-TKIs. But before exposure to EGFR TKIs, patients with baseline EGFR T790M were detected by standard molecular analysis in our study. The incidence of primary T790M ranged from 1% to 25% depending on the detection method and the population tested (24). Generally, De novo T790M occurred concurrently with sensitive mutations as observed in our research (25). Proved by previous and current studies, De novo EGFR T790M mutations had limited benefit from EGFR-TKIs and reduced the sensitivity of classical active mutations (24). According to previous studies, 3.19% 15% of patients with EGFR mutations had complex mutations (26,27). In this study, most complex mutations contained the 19 del or L858R mutations, and the result suggested that the concomitant occurrence of 19 del and L858R might be a strong predictive factor in terms of the efficacy of EGFR
6 Chinese Journal of Cancer Research, Vol 29, No 1 February TKIs. Earlier studies showed that patients with 19 del + L858R mutations had a median PFS of months after TKI treatment (21,28). Furthermore, 19 del or L858R + rare mutations also seemed to be strong predictors of sensitivity. In current study, 2 patients with L858R + 19 del achieved PR and PFS of 6.0 months and 6.2 months, respectively. Consistent with previous studies, patients in our study who had a T790M mutation in addition to an L858R or 19 del mutation failed to demonstrate a superior response to EGFR TKI therapy, although contained an L858R or 19 del mutation. Therefore, first-generation TKIs such as erlotinib, gefitinib and icotinib maybe the optimal choice of therapy for patients with complex mutations containing 19 del or L858R mutations but not T790M. The major limitation of this study is its retrospective design. Besides, uncommon EGFR mutations are heterogeneous and should be analyzed separately. However, due to its low incidence, the sample size in each subgroup is rather small. We therefore had to integrate the diverse mutations into one group and made conclusions combining with previous literature. Conclusions Uncommon EGFR-mutant NSCLC is a group of rare diseases with heterogeneity, and EGFR-TKIs can have different efficacy in specific subtypes. Thus, further individual assessment is required for each case. Acknowledgements This study was supported by the funding from Chinese Geriatric Oncology Society (CGOS) (No. H08151). Footnote Conflicts of Interest: The authors have no conflicts of interest to declare. References Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer J Clin 2016;66:7-30. Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, Chin J Cancer Res 2016;28:1-11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12: Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology Mainland China subset analysis of the PIONEER study. PLoS One 2015;10:e Chiu CH, Yang CT, Shih JY, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol 2015;10: Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11: Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15: Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17: Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-
7 24 Zhang et al. NSCLC with uncommon EGFR small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX- Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16: Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-smallcell lung cancer on 10,117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2014;25: De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6: Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14: Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e Oxnard GR, Jänne PA. Power in numbers: metaanalysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 2013;19: Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010;40: Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines insights: non-small cell lung cancer, Version J Natl Compr Canc Netw 2016; 14: Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277: Xu J, Jin B, Chu T, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer 2016;96: Hsieh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006;53: Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177. Yu HA, Arcila ME, Hellmann MD, et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014;25: Peng L, Song ZG, Jiao SC. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 2014;4:6104. Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8: Liu Y, Wu BQ, Zhong HH, et al. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. Int J Clin Exp Pathol 2013;6: Keam B, Kim DW, Park JH, et al. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol 2014;19: Cite this article as: Zhang Y, Wang Z, Hao X, Hu X, Wang H, Wang Y, Ying J. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations. Chin J Cancer Res 2017;29(1): doi: /j.issn
Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased
Original Article Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinumbased chemotherapy Jinpeng Shi 1*, Hui Yang 1*, Tao Jiang 1, Xuefei Li 2,
More informationEGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-018-0281-1 August 2018, Vol. 4, No. 4, P158 P162 ORIGINAL ARTICLE Treatment and survival status of patients with EGFR mutation-positive stage IV lung
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationCheng-Zhi Zhou*, Yin-Yin Qin*, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ou-Yang, Shi-Yue Li, Rong- Chang Chen
Original Article Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma Cheng-Zhi Zhou*, Yin-Yin
More informationChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)
Consensus Page 1 of 5 China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version) Yuankai Shi 1, Yan Sun 1, Cuimin Ding 2, Ziping Wang 1, Changli Wang 3, Zheng Wang 4, Chong
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationIntroduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
More informationEditorial Process: Submission:10/27/2017 Acceptance:05/25/2018
DOI:10.22034/APJCP.2018.19.7.1761 TKI by Liquid Biopsy RESEARCH ARTICLE Editorial Process: Submission:10/27/2017 Acceptance:05/25/2018 A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationOriginal Article. Abstract
Original Article Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis Minglei Zhuo 1*, Qiwen Zheng
More informationPostoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
Yang et al. World Journal of Surgical Oncology (2017) 15:197 DOI 10.1186/s12957-017-1251-z RESEARCH Open Access Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients
More informationIntroduction. Methods. Patient and study design
Original Article Continuation of gefitinib plus chemotherapy prolongs progressionfree survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationEfficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer
Original Article Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer Aiqin Gu, Chunlei Shi, Liwen Xiong, Tianqing Chu, Jun Pei, Baohui Han Department of pulmonary
More informationCorrespondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
More informationLung cancer is ranked as the most common cause of cancer
BRIEF REPORT Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors Susumu Kobayashi, MD, PhD, Hannah M. Canepa, BA, Alexandra S. Bailey, MD, Sohei Nakayama, MD, PhD, Norihiro Yamaguchi,
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationABSTRACT. PERMANYER. J Cancerol. 2015;2:56-63
www.journalofcancerology.com PERMANYER J Cancerol. 2015;2:56-63 JOURNAL OF CANCEROLOGY REVIEW ARTICLE Outcome of Patients with Lung Adenocarcinoma Harboring Common and Rare Epidermal Growth Factor Receptor
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationT he utility of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in metastatic nonsmall
OPEN SUBJECT AREAS: NON-SMALL-CELL LUNG CANCER TARGETED THERAPIES Received 30 April 2014 Accepted 15 July 2014 Published 8 August 2014 Correspondence and requests for materials should be addressed to H.L.
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationSurvival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
More informationExon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationShaohua Cui, Liwen Xiong, Yuqing Lou, Huangping Shi, Aiqin Gu, Yizhuo Zhao, Tianqing Chu, Huimin Wang, Wei Zhang, Lili Dong, Liyan Jiang
Original Article Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors Shaohua Cui, Liwen Xiong,
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationBiomedical Research 2017; 28 (14): ISSN X
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases
Original Article Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Yuan-Yuan Lei 1,2, Jin-Ji Yang 2, Wen-Zhao Zhong 2, Hua-Jun Chen
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationAdjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Editorial Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? Giandomenico Roviello 1, Marco Imperatori 1, Michele Aieta 1, Francesco Sollitto 2, Matteo Landriscina
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationYong Zhang 1#, Ling Ye 1#, Huijun Zhang 1, Xuehua Chen 1, Haiying Ji 1, Gang Chen 1, Lu Zhang 2, Tengfei Zhang 2, Meiling Jin 1.
Case Report A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors Yong Zhang 1#, Ling Ye 1#,
More informationLung cancer is the leading cause of cancer related death
Original Article Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non Small-Cell Lung Cancer Jih-Hsiang Lee, MD,* Yu-Lin Lin, MD,* Wei-Hsun Hsu, MD,* Hsuan-Yu Chen, PhD, # Yeun-Chung
More informationFrequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
More informationLung cancer represents the leading cause of death from
ORIGINAL ARTICLE Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations Kenichi Nishie, MD,*
More informationRESEARCH ARTICLE. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
RESEARCH ARTICLE EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer Satoshi Igawa 1 *, Yuichi Sato 2, Mikiko Ishihara 1, Masashi Kasajima
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationShort Report Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
IJC Short Report Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC International Journal of Cancer Jinguang Wang 1, Xingya Li 2, Xingyang Xue 3, Qiuxiang Ou Yang W. Shao
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationCarmen Salvador-Coloma 1,2, David Lorente 1,2, Sarai Palanca 3, Javier Simarro 3, Nuria Mancheño 4, Juan Sandoval 5, Agustín Lahoz 5, Óscar Juan 2,5
Original Article Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations Carmen Salvador-Coloma 1,2,
More informationAdjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Editorial Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine Peng Shen 1, Wenzhao Zhong 2 1 Department of Oncology, Nanfang Hospital, Southern Medical
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationClinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Jpn J Clin Oncol 2012;42(6)528 533 doi:10.1093/jjco/hys042 Advance Access Publication 28 March 2012 Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationPersonalized Medicine in Oncology and the Implication for Clinical Development
THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success
More informationCHAPTER 8A. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well
CHAPTER 8A High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases one with a remarkable thoracic response as well J.L. Kuiper, E.F. Smit Lung Cancer 2013 Apr;80(1):102-5 Chapter
More informationClinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during
Original Article Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011 2015 Pingli Wang 1 *, Jixia Zou 1 *, Jingni Wu 1 *, Chengyan Zhang
More informationLu Xu 1#, Xin-Hua Xu 2, Cheng Yuan 3#, Jia-Yu Zhang 1#, Xi Tang 4, Dian Chen 5, Xiao-Long Wang 6, Guang Zeng 7. Original Article
Original Article Page 1 of 8 Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationThe identification of epidermal growth factor receptor
Original Article Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 2 Insertions Geoffrey R. Oxnard, MD,* Peter C. Lo,* Mizuki Nishino, MD, Suzanne E. Dahlberg, PhD, Neal
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More information(27) Indeed, afatinib was reported to be clinically effective. (28) Although this study also indicated the efficacy of
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor
More informationIrreversible EGFR-TKIs: dreaming perfection
Review Article Irreversible EGFR-TKIs: dreaming perfection Lorenza Landi, Federico Cappuzzo Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy Corresponding to: Federico Cappuzzo,
More informationMOLECULAR AND CLINICAL ONCOLOGY 1: , 2013
MOLECULAR AND CLINICAL ONCOLOGY 1: 711-715, 2013 Clinical study on gefitinib combined with γ ray stereotactic body radiation therapy as the first line treatment regimen for senile patients with adenocarcinoma
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationShingo Nishikawa, Hideharu Kimura, Hayato Koba, Taro Yoneda, Satoshi Watanabe, Tamami Sakai, Johsuke Hara, Takashi Sone, Kazuo Kasahara, Shinji Nakao
Original Article Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine
More informationPresented at the European Society of Medical Oncology (ESMO), Munich, Germany, October 2018
Effectiveness of afatinib in clinical practice first results of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC in Germany Wolfgang M. Brueckl 1 *, Eckart Laack 2, Martin
More informationRead, Interpret, and Communicate Test Results
Read, Interpret, and Communicate Test Results Effective interpretation of epidermal growth factor receptor (EGFR) T790M mutation test results at progression will help physicians to set patient expectations
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
774 Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation positive non small cell lung cancer, receiving treatment
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationOsimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Editorial : a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma Niki Karachaliou 1, Feliciano Barron Barron 2, Santiago Viteri 3, Miguel Angel Molina 4, Rafael
More informationResearch Article The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
BioMed Research International Volume 215, Article ID 948267, 8 pages http://dx.doi.org/1.1155/215/948267 Research Article The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationExpression of HGF, MET and mutated EGFR in EGFR mutated lung adenocarcinoma and their clinical significance
Original Article Expression of HGF, MET and mutated EGFR in EGFR mutated lung adenocarcinoma and their clinical significance Shu-Ling Zhang, Xin Sun, Li Sun, Zhi-Cheng Xiong, Jie-Tao Ma, Le-Tian Huang,
More informationEpidermal growth factor receptor (EGFR) mutations are
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationRecurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports Puyuan
More information